The Journal of Practical Medicine ›› 2021, Vol. 37 ›› Issue (11): 1382-1386.doi: 10.3969/j.issn.1006⁃5725.2021.11.002

• Clinical Advances • Previous Articles     Next Articles

Endocrine toxicity of immune checkpoint inhibitors and clinical response strategies 

YE Qiang，CHEN Xiaoyan.    

  1. Guangzhou Medical University，Guangzhou 511436，China；*Fuyong People′ s Hospital of Baoan Dis⁃ trict，Shenzhen 518000，China 

  • Online:2021-06-10 Published:2021-06-10
  • Contact: CHEN Xiaoyan E⁃mail：gzscxy@126.com

Abstract:

Immune checkpoint inhibitors（ICPIs）including anti ⁃cytotoxic T lymphocyte antigen 4，anti ⁃ programmed cell death 1 and anti⁃programmed cell death 1 ligand antibodies are novel therapeutic agents targeting a variety of cancers and show good therapeutic effect in clinical practice. However，a wide range of immune⁃related adverse reactions（irAEs）are reported during their application，during which the endocrine organ damage is the most common，and it affects the anti⁃tumor effect and patient′s quality of life.This article reviews the clinical char⁃ acteristics，possible pathogenesis and management strategies of immune⁃related adverse reactions of ICPIs therapy. 

Key words:

immune checkpoint inhibitors, endocrine organs, immune?related adverse reactions